[
  {
    "ts": null,
    "headline": "Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs",
    "summary": "WILMINGTON, Del., November 18, 2024--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs",
    "url": "https://finnhub.io/api/news?id=48e4894d03d9818c81824e4f9a50b85f709fe5ecacc4deef6944f5fbd6984d94",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731965400,
      "headline": "Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs",
      "id": 131466865,
      "image": "https://media.zenfs.com/en/business-wire.com/993c1cdc02eb7356eeb430115603e137",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "WILMINGTON, Del., November 18, 2024--Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs",
      "url": "https://finnhub.io/api/news?id=48e4894d03d9818c81824e4f9a50b85f709fe5ecacc4deef6944f5fbd6984d94"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
    "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=0ce9f5e652983e0fbf009ec1591789a7ca8cd7f2d6cd125fcbdf434bc4d02ed1",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731950100,
      "headline": "Incyte Corp. stock outperforms competitors on strong trading day",
      "id": 131615123,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=0ce9f5e652983e0fbf009ec1591789a7ca8cd7f2d6cd125fcbdf434bc4d02ed1"
    }
  },
  {
    "ts": null,
    "headline": "Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?",
    "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Incyt Corporation (NASDAQ:INCY) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]",
    "url": "https://finnhub.io/api/news?id=a19b2cea9fea1df9accd6df7fb8842bf186e5b40823d503147c09792cc2d666b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731936514,
      "headline": "Is Incyt Corporation (INCY) the Best Immunotherapy Stock to Buy Now?",
      "id": 131441245,
      "image": "https://s.yimg.com/ny/api/res/1.2/rh_uYxHoXH89gYNRrkZAyQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02NzM-/https://media.zenfs.com/en/insidermonkey.com/1cc545eb3596ed209c0c0486654a1d8d",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at where Incyt Corporation (NASDAQ:INCY) stands against the other immunotherapy stocks. The global immunotherapy drugs market is rapidly expanding, with projections to grow from $240 billion in 2023 to $1.3 trillion by […]",
      "url": "https://finnhub.io/api/news?id=a19b2cea9fea1df9accd6df7fb8842bf186e5b40823d503147c09792cc2d666b"
    }
  }
]